An analysis of biotinidase deficiency

The risk of biotinidase deficiency occurring in the offspring of an individual with biotinidase deficiency is essentially zero if the reproductive partner is not heterozygous for a BTD pathogenic variant. Long-term treatment may include dietary protein restriction and carnitine supplementation.

Errors in our interpretation of results may occur if information given is inaccurate or incomplete. AspHis in one allele of BTD in combination with a pathogenic variant for profound deficiency in the other allele [ Swango et al ].

These alleles are considered profound biotinidase deficiency alleles; a combination of two such alleles, whether homozygous or compound heterozygousresults in profound biotinidase deficiency. Assay of individual carboxylases in white blood cells will show deficiency of all three carboxylases assayed, but this is not specific.

Biotinidase Deficiency

In other individuals with enzyme deficiency, paresis and eye problems have occurred during early adolescence [ Tokatli et alWolf et alWolf ]. Surveillance For all children with biotinidase deficiency: Several adults with profound biotinidase deficiency have never had symptoms and have never been treated [ Wolf et al ] whereas some children with the same pathogenic variants have been symptomatic.

If left untreated, the disorder can rapidly lead to coma and death.

As not all states require that this test be done, it is often skipped in those where such testing is not required. Treatment with biotin has been successful in both preventing and reversing the clinical features associated with biotinidase deficiency.

Two large BTD deletions have been reported in affected individuals [ Senanayake et alWolf ]. Several reports describe adults with profound biotinidase deficiency who have offspring who also have profound biotinidase deficiency identified by newborn screeningbut who have never had symptoms [ Wolf et alBaykal et al ].

Studies [1] [2] have noted individuals who were asymptomatic until adolescence or early adulthood. One child with partial biotinidase deficiency who was not treated with biotin exhibited hypotonia, skin rash, and hair loss during an episode of gastroenteritis at approximately age six months.

Carrier testing for at-risk relatives requires prior identification of the BTD pathogenic variants in the family. Age of onset and clinical phenotype vary among individuals.

Biotinidase deficiency

Evaluation of urinary organic acids if return of symptoms with biotin therapy most commonly the result of non-compliance Note: For issues to consider in interpretation of sequence analysis results, click here.

Genet Med May;17 5: Without biotinidase activity, the vitamin biotin cannot be separated from foods and therefore cannot be used by the body. However, the tandem mass spectroscopic methodology that is being incorporated into many newborn screening programs should identify metabolites that are consistent with multiple carboxylase deficiency.

Carrier Heterozygote Detection Molecular genetic testing. The activities of the carboxylases in fibroblasts of individuals with holocarboxylase synthetase deficiency become near-normal to normal when cultured in medium supplemented with biotin high biotin.

Nomenclature Profound and partial biotinidase deficiency is the accepted nomenclature for this disorder. New York, Oxford University Press, pp 5. Neurologic problems occur only in those individuals with biotinidase deficiency who have recurrent symptoms and metabolic compromise prior to biotin treatment.

The free biotin is then covalently attached to the various apocarboxylases, propionyl-CoA carboxylase more The most common neurologic features in individuals with untreated, profound biotinidase deficiency are seizures and hypotonia [ Wolf et al aWolf et al bWastell et alWolfWolf ].

The name avidin literally means that this protein has an "avidity" Latin: Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. Biotinidase deficiency is inherited in an autosomal recessive manner, caused by mutations in the biotinidase gene BTD.

Therefore, measurement of the biotinidase enzyme is required to differentiate between these diseases and ensure proper diagnosis. This is often done at birth as part of newborn screening in several states throughout the United States.

Some treated children have rapidly achieved developmental milestones, whereas others have continued to show delays. Biotin is a vitamin that is chemically bound to proteins. Biotinidase deficiency can also be found by sequencing the BTD gene, particularly in those with a family history or known familial gene mutation.

Sequence analysis detects variants that are benign, likely benign, of uncertain significancelikely pathogenic, or pathogenic. Organic acid abnormalities in biotinidase deficiency and holocarboxylase synthetase deficiency are similar and may be reported as consistent with multiple carboxylase deficiency.Biotinidase deficiency (BTD) is an autosomal recessive metabolic disorder in which biotin is not released from proteins in the diet during digestion or from normal protein turnover in the cell.

This situation results in biotin deficiency. Biotin, also called vitamin B 7, is an important water-soluble nutrient that aids in the metabolism of fats, carbohydrates, and. Biotinidase deficiency is typically detected very early because of newborn screening programs, which measure biotinidase activity in dried blood spots.

Indications Measurement of biotinidase activity in plasma or serum is available to confirm a new diagnosis and to determine whether the patient has partial or complete biotinidase. Mutation analysis of the entire biotinidase gene is rarely necessary, because there are no therapeutic consequences with the exception of individuals with partial biotinidase deficiency in which targeted mutation analysis may be helpful (Wolf, ).

If untreated, young children with profound biotinidase deficiency usually exhibit neurologic abnormalities including seizures, hypotonia, ataxia, developmental delay, vision problems, hearing loss, and cutaneous abnormalities (e.g., alopecia, skin rash, candidiasis).

Older children and adolescents with profound biotinidase deficiency often exhibit motor limb. Clinical Information. Biotinidase deficiency is an inherited metabolic disease caused by reduced levels of biotinidase, an enzyme that recycles biotin by releasing it from its metabolic product, biocytin, or exogenous dietary proteins.

Biotinidase deficiency Methodology Help The assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e.

the name of the method used) and instruments used when performing this test.

An analysis of biotinidase deficiency
Rated 3/5 based on 86 review